Houghton PJ - Search Results

1

The TOR pathway: a target for cancer therapy.

Bjornsti MA, Houghton PJ. Bjornsti MA, et al. Among authors: houghton pj. Nat Rev Cancer. 2004 May;4(5):335-48. doi: 10.1038/nrc1362. Nat Rev Cancer. 2004. PMID: 15122205 Review. No abstract available.

2

Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.

Hosoi H, Dilling MB, Shikata T, Liu LN, Shu L, Ashmun RA, Germain GS, Abraham RT, Houghton PJ. Hosoi H, et al. Among authors: houghton pj. Cancer Res. 1999 Feb 15;59(4):886-94. Cancer Res. 1999. PMID: 10029080

3

p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.

Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ. Huang S, et al. Among authors: houghton pj. Cancer Res. 2001 Apr 15;61(8):3373-81. Cancer Res. 2001. PMID: 11309295

4

Resistance to rapamycin: a novel anticancer drug.

Huang S, Houghton PJ. Huang S, et al. Among authors: houghton pj. Cancer Metastasis Rev. 2001;20(1-2):69-78. doi: 10.1023/a:1013167315885. Cancer Metastasis Rev. 2001. PMID: 11831650 Review.

5

Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin.

Shu L, Zhang X, Houghton PJ. Shu L, et al. Among authors: houghton pj. J Biol Chem. 2002 May 10;277(19):16726-32. doi: 10.1074/jbc.M112285200. Epub 2002 Mar 1. J Biol Chem. 2002. PMID: 11875068 Free article.

6

Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture.

Zhang X, Shu L, Hosoi H, Murti KG, Houghton PJ. Zhang X, et al. Among authors: houghton pj. J Biol Chem. 2002 Aug 2;277(31):28127-34. doi: 10.1074/jbc.M202625200. Epub 2002 May 8. J Biol Chem. 2002. PMID: 12000755 Free article.

7

Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.

Huang S, Houghton PJ. Huang S, et al. Among authors: houghton pj. Curr Opin Investig Drugs. 2002 Feb;3(2):295-304. Curr Opin Investig Drugs. 2002. PMID: 12020063 Review.

8

Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.

Thimmaiah KN, Easton J, Huang S, Veverka KA, Germain GS, Harwood FC, Houghton PJ. Thimmaiah KN, et al. Among authors: houghton pj. Cancer Res. 2003 Jan 15;63(2):364-74. Cancer Res. 2003. PMID: 12543789

9

Rapamycins: mechanism of action and cellular resistance.

Huang S, Bjornsti MA, Houghton PJ. Huang S, et al. Among authors: houghton pj. Cancer Biol Ther. 2003 May-Jun;2(3):222-32. doi: 10.4161/cbt.2.3.360. Cancer Biol Ther. 2003. PMID: 12878853 Review.

10

Targeting mTOR signaling for cancer therapy.

Huang S, Houghton PJ. Huang S, et al. Among authors: houghton pj. Curr Opin Pharmacol. 2003 Aug;3(4):371-7. doi: 10.1016/s1471-4892(03)00071-7. Curr Opin Pharmacol. 2003. PMID: 12901945 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

589 results

Search Page